You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.


KEDPLASMA USA Continues to Advance Long-Range Growth Plan; Acquires Additional Plasma Collection Centers in Florida & North Carolina

KEDPLASMA USA, one of the world’s leading collectors of high-quality human blood plasma, has announced the acquisition of two additional plasma collection centers from ImmunoTek Bio Centers, LLC, effective on April 1, 2017. KEDPLASMA USA’s acquisition of the two plasma collection centers, which are located in Kissimmee, Florida, and Burlington, North Carolina, is another step forward in a five-year strategic plan to double the number of centers the Company operates so that more patients may have access to the therapies offered by Kedrion Biopharma.

KEDPLASMA USA collects plasma for Kedrion Biopharma Inc., which, in turn, uses it in the production of safe, effective, plasma-derived therapies that treat a range of rare and serious health conditions, including hemophiliaimmunological and neurological conditions, and certain acute, life-threatening conditions requiring treatment in the critical care setting.

KEDPLASMA USA is also one of the largest suppliers of high rabies antibody titer plasma in the world. Its parent company, Kedrion Biopharma Inc., is a subsidiary of Kedrion S.p.A. (Kedrion Biopharma).

“With the addition of these two centers, along with the ongoing expansion that KEDPLASMA USA is undergoing, we continue to expand our capability to meet the increasing requirements of our parent company, Kedrion Biopharma. This allows the Company to manufacture and distribute the critical therapies so needed by patients who have certain rare and serious health conditions,” said Helen Nasser, KEDPLASMA USA Managing Director. “It is always exciting to welcome new personnel and donors to the KEDPLASMA USA family.”

All centers owned and operated by KEDPLASMA USA are licensed and regulated by the U.S. Food and Drug Administration and are approved and monitored by the relevant European healthcare regulation authorities.

ImmunoTek Bio Centers, LLC CEO and President, Jerome Parnell III, said, “The transition of these assets to KEDPLASMA USA represents ImmunoTek’s ability to provide maximum flexibility to all of our customers as they seek to fulfill their strategic plasma supply needs. It also further enhances our relationship with Kedrion Biopharma, a strong partner in the global biopharma market.”

For more information please contact: